skip to content

Cambridge Public Health

 

infectious agents and cancer
biology of cervical epithelium and how and why cancer of the cervix develops;
current research focuses on mechanisms of host defence and the development of vaccines and immunotherapies against human papillomaviruses, the cause of cervix cancer

Publications from Elements

Journal articles

2016

  • Van Damme, P., Bonanni, P., Bosch, FX., Joura, E., Kjaer, SK., Meijer, CJLM., Petry, K-U., Soubeyrand, B., Verstraeten, T. and Stanley, M., 2016. Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757-761]. Vaccine, v. 34
    Doi: http://doi.org/10.1016/j.vaccine.2016.07.035
  • Radley, D., Saah, A. and Stanley, M., 2016. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother, v. 12
    Doi: http://doi.org/10.1080/21645515.2015.1088616
  • Hernández-Ávila, M., Torres-Ibarra, L., Stanley, M., Salmerón, J., Cruz-Valdez, A., Muñoz, N., Herrero, R., Villaseñor-Ruíz, IF. and Lazcano-Ponce, E., 2016. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother, v. 12
    Doi: http://doi.org/10.1080/21645515.2015.1058458
  • Van Damme, P., Bonanni, P., Bosch, FX., Joura, E., Kjaer, SK., Meijer, CJLM., Petry, K-U., Soubeyrand, B., Verstraeten, T. and Stanley, M., 2016. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine, v. 34
    Doi: http://doi.org/10.1016/j.vaccine.2015.12.063
  • Stanley, M., 2016. HPV vaccines: how many doses are needed for protection? FUTURE VIROLOGY, v. 11
    Doi: http://doi.org/10.2217/fvl-2016-0008
  • Hendry, M., Pasterfield, D., Adams, R., Evans, M., Fiander, A., Robling, M., Campbell, C., Makin, M., Gollins, S., Hiscock, J., Nafees, S., Bekkers, M-J., Rose, J., Williams, O., Stanley, M. and Wilkinson, C., 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open, v. 6
    Doi: http://doi.org/10.1136/bmjopen-2016-011205
  • Stanley, M., 2016. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines? J Infect, v. 72 Suppl
    Doi: http://doi.org/10.1016/j.jinf.2016.04.018
  • 2015

  • Lowy, DR., Herrero, R., Hildesheim, A. and Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials, , 2015. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol, v. 16
    Doi: http://doi.org/10.1016/S1470-2045(15)70075-6
  • Garland, SM., Subasinghe, AK., Jayasinghe, YL., Wark, JD., Moscicki, A-B., Singer, A., Bosch, X., Cusack, K. and Stanley, M., 2015. HPV vaccination for victims of childhood sexual abuse. Lancet, v. 386
    Doi: http://doi.org/10.1016/S0140-6736(15)00757-6
  • 2014

  • Stanley, MA., Sudenga, SL. and Giuliano, AR., 2014. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines, v. 13
    Doi: http://doi.org/10.1586/14760584.2014.935767
  • Stanley, M., O'Mahony, C. and Barton, S., 2014. HPV vaccination. BMJ, v. 349
    Doi: http://doi.org/10.1136/bmj.g4783
  • Stanley, M., 2014. HPV vaccination in boys and men. Hum Vaccin Immunother, v. 10
    Doi: http://doi.org/10.4161/hv.29137
  • Stanley, M., 2014. HPV vaccination in boys and men. Hum Vaccin Immunother, v. 10
    Doi: http://doi.org/10.4161/hv.29138
  • Stanley, M., 2014. HPV vaccination in boys and men. Hum Vaccin Immunother, v. 10
    Doi: http://doi.org/10.4161/hv.29138
  • Lazcano-Ponce, E., Stanley, M., Muñoz, N., Torres, L., Cruz-Valdez, A., Salmerón, J., Rojas, R., Herrero, R. and Hernández-Ávila, M., 2014. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine, v. 32
    Doi: http://doi.org/10.1016/j.vaccine.2013.11.059
  • Lazcano-Ponce, E., Stanley, M., Muñoz, N., Torres, L., Cruz-Valdez, A., Salmerón, J., Rojas, R., Herrero, R. and Hernández-Ávila, M., 2014. Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months Vaccine, v. 32
    Doi: http://doi.org/10.1016/j.vaccine.2013.11.059
  • Stanley, MA. and Sterling, JC., 2014. Host responses to infection with human papillomavirus. Curr Probl Dermatol, v. 45
    Doi: http://doi.org/10.1159/000355964
  • Stanley, M., 2014. HPV vaccination in boys and men. Hum Vaccin Immunother, v. 10
  • 2013

  • Hawkins, MG., Winder, DM., Ball, SLR., Vaughan, K., Sonnex, C., Stanley, MA., Sterling, JC. and Goon, PKC., 2013. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J, v. 10
    Doi: http://doi.org/10.1186/1743-422X-10-137
  • Hanning, JE., Saini, HK., Murray, MJ., Caffarel, MM., van Dongen, S., Ward, D., Barker, EM., Scarpini, CG., Groves, IJ., Stanley, MA., Enright, AJ., Pett, MR. and Coleman, N., 2013. Depletion of HPV16 early genes induces autophagy and senescence in a cervical carcinogenesis model, regardless of viral physical state. J Pathol, v. 231
    Doi: http://doi.org/10.1002/path.4244
  • Bosch, FX., Broker, TR., Forman, D., Moscicki, A-B., Gillison, ML., Doorbar, J., Stern, PL., Stanley, M., Arbyn, M., Poljak, M., Cuzick, J., Castle, PE., Schiller, JT., Markowitz, LE., Fisher, WA., Canfell, K., Denny, LA., Franco, EL., Steben, M., Kane, MA., Schiffman, M., Meijer, CJLM., Sankaranarayanan, R., Castellsagué, X., Kim, JJ., Brotons, M., Alemany, L., Albero, G., Diaz, M., de Sanjosé, S. and authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012, , 2013. Comprehensive control of human papillomavirus infections and related diseases. Vaccine, v. 31 Suppl 7
    Doi: http://doi.org/10.1016/j.vaccine.2013.10.003
  • Bosch, FX., Broker, TR., Forman, D., Moscicki, A-B., Gillison, ML., Doorbar, J., Stern, PL., Stanley, M., Arbyn, M., Poljak, M., Cuzick, J., Castle, PE., Schiller, JT., Markowitz, LE., Fisher, WA., Canfell, K., Denny, LA., Franco, EL., Steben, M., Kane, MA., Schiffman, M., Meijer, CJLM., Sankaranarayanan, R., Castellsagué, X., Kim, JJ., Brotons, M., Alemany, L., Albero, G., Diaz, M., de Sanjosé, S. and authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012, , 2013. Comprehensive control of human papillomavirus infections and related diseases. Vaccine, v. 31 Suppl 5
    Doi: http://doi.org/10.1016/j.vaccine.2013.10.001
  • Bosch, FX., Broker, TR., Forman, D., Moscicki, A-B., Gillison, ML., Doorbar, J., Stern, PL., Stanley, M., Arbyn, M., Poljak, M., Cuzick, J., Castle, PE., Schiller, JT., Markowitz, LE., Fisher, WA., Canfell, K., Denny, LA., Franco, EL., Steben, M., Kane, MA., Schiffman, M., Meijer, CJLM., Sankaranarayanan, R., Castellsagué, X., Kim, JJ., Brotons, M., Alemany, L., Albero, G., Diaz, M., de Sanjosé, S. and ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012, , 2013. Comprehensive control of human papillomavirus infections and related diseases. Vaccine, v. 31 Suppl 6
    Doi: http://doi.org/10.1016/j.vaccine.2013.10.002
  • Xavier Bosch, F., Broker, TR., Forman, D., Moscicki, A-B., Gillison, ML., Doorbar, J., Stern, PL., Stanley, M., Arbyn, M., Poljak, M., Cuzick, J., Castle, PE., Schiller, JT., Markowitz, LE., Fisher, WA., Canfell, K., Denny, LA., Franco, EL., Steben, M., Kane, MA., Schiffman, M., Meijer, CJLM., Sankaranarayanan, R., Castellsague, X., Kim, JJ., Brotons, M., Alemany, L., Albero, G., Diaz, M. and de Sanjose, S., 2013. Comprehensive Control of Human Papillomavirus Infections and Related Diseases VACCINE, v. 31
    Doi: http://doi.org/10.1016/j.vaccine.2013.07.026
  • 2012

  • Stanley, MA., 2012. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol, v. 93
    Doi: http://doi.org/10.1099/vir.0.039677-0
  • Stanley, MA., 2012. Epithelial cell responses to infection with human papillomavirus Clinical Microbiology Reviews, v. 25
    Doi: http://doi.org/10.1128/CMR.05028-11
  • Stanley, M., 2012. Perspective: Vaccinate boys too. Nature, v. 488
    Doi: http://doi.org/10.1038/488S10a
  • Stanley, M., 2012. Perspective: Vaccinate boys too Nature, v. 488
    Doi: http://doi.org/10.1038/488S10a
  • Stanley, MA., Winder, DM., Sterling, JC. and Goon, PKC., 2012. HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues. BMC Cancer, v. 12
    Doi: http://doi.org/10.1186/1471-2407-12-398
  • Stanley, M., Pinto, LA. and Trimble, C., 2012. Human papillomavirus vaccines--immune responses. Vaccine, v. 30 Suppl 5
    Doi: http://doi.org/10.1016/j.vaccine.2012.04.106
  • Franco, EL., de Sanjose, S., Broker, TR., Stanley, MA., Chevarie-Davis, M., Isidean, SD. and Schiffman, M., 2012. Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy VACCINE, v. 30
    Doi: http://doi.org/10.1016/j.vaccine.2012.06.092
  • Doorbar, J., Quint, W., Banks, L., Bravo, IG., Stoler, M., Broker, TR. and Stanley, MA., 2012. The Biology and Life-Cycle of Human Papillomaviruses VACCINE, v. 30
    Doi: http://doi.org/10.1016/j.vaccine.2012.06.083
  • 2011

  • Shafi, MI., Petry, U., Bosch, XF., Gissman, L., Kocken, M., Helmerhorst, TJM., Stanley, M. and Nazeer, S., 2011. European Consensus Statement on "HPV Vaccination and Colposcopy" J LOW GENIT TRACT DI, v. 15
    Doi: http://doi.org/10.1097/LGT.0b013e318222b2c4
  • Ball, SLR., Winder, DM., Vaughan, K., Hanna, N., Levy, J., Sterling, JC., Stanley, MA. and Goon, PKC., 2011. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol, v. 83
    Doi: http://doi.org/10.1002/jmv.22111
  • Sudhoff, HH., Schwarze, HP., Winder, D., Steinstraesser, L., Görner, M., Stanley, M. and Goon, PKC., 2011. Evidence for a causal association for HPV in head and neck cancers European Archives of Oto-Rhino-Laryngology,
  • Crawford, R., Grignon, A-L., Kitson, S., Winder, DM., Ball, SLR., Vaughan, K., Stanley, MA., Sterling, JC. and Goon, PKC., 2011. High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology. BMC Cancer, v. 11
    Doi: http://doi.org/10.1186/1471-2407-11-473
  • Sudhoff, HH., Schwarze, HP., Winder, D., Steinstraesser, L., Görner, M., Stanley, M. and Goon, PKC., 2011. Evidence for a causal association for HPV in head and neck cancers European Archives of Oto-Rhino-Laryngology, v. 268
    Doi: http://doi.org/10.1007/s00405-011-1714-8
  • 2010

  • Gray, E., Pett, MR., Ward, D., Winder, DM., Stanley, MA., Roberts, I., Scarpini, CG. and Coleman, N., 2010. In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res, v. 70
    Doi: http://doi.org/10.1158/0008-5472.CAN-09-3335
  • Stanley, M., 2010. HPV - immune response to infection and vaccination. Infect Agent Cancer, v. 5
    Doi: http://doi.org/10.1186/1750-9378-5-19
  • Stanley, M., 2010. HPV VACCINES: AN OVERVIEW ACTA CYTOL, v. 54
  • Stanley, M., 2010. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol, v. 118
    Doi: http://doi.org/10.1016/j.ygyno.2010.04.002
  • Stanley, M., 2010. Prospects for new human papillomavirus vaccines CURR OPIN INFECT DIS, v. 23
    Doi: http://doi.org/10.1097/QCO.0b013e328334c0e1
  • Stanley, M., 2010. HPV - Immune response to infection and vaccination Infectious Agents and Cancer, v. 5
    Doi: http://doi.org/10.1186/1750-9378-5-19
  • Stanley, M., 2010. Pathology and epidemiology of HPV infection in females GYNECOL ONCOL, v. 117
    Doi: http://doi.org/10.1016/j.ygyno.2010.01.024
  • Stanley, M., 2010. Potential mechanisms for HPV vaccine-induced long-term protection Gynecologic Oncology, v. 118
    Doi: http://doi.org/10.1016/j.ygyno.2010.04.002
  • O'Mahony, C., Yesudian, PD. and Stanley, M., 2010. Imiquimod use in the genital area and development of lichen sclerosus and lichen planus INT J STD AIDS, v. 21
    Doi: http://doi.org/10.1258/ijsa.2009.009154
  • Stanley, M., 2010. Pathology and epidemiology of HPV infection in females Gynecologic Oncology, v. 117
    Doi: http://doi.org/10.1016/j.ygyno.2010.01.024
  • Stanley, M., 2010. Prophylactic human papillomavirus vaccines: will they do their job? J INTERN MED, v. 267
    Doi: http://doi.org/10.1111/j.1365-2796.2009.02193.x
  • Woo, YL., van den Hende, M., Sterling, JC., Coleman, N., Crawford, RAF., Kwappenberg, KMC., Stanley, MA. and van der Burg, SH., 2010. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer, v. 126
    Doi: http://doi.org/10.1002/ijc.24804
  • 2009

  • Goon, PKC., Stanley, MA., Ebmeyer, J., Steinsträsser, L., Upile, T., Jerjes, W., Bernal-Sprekelsen, M., Görner, M. and Sudhoff, HH., 2009. HPV & head and neck cancer: a descriptive update. Head Neck Oncol, v. 1
    Doi: http://doi.org/10.1186/1758-3284-1-36
  • Stanley, M., 2009. Immunobiology of genital HPV infection CME Journal of Gynecologic Oncology, v. 14
  • Stanley, M., 2009. HPV genital tract infection: Molecular pathogenesis CME Journal of Gynecologic Oncology, v. 14
  • Heaps, A., Hanna, N., Stanley, M. and Goon, P., 2009. Ex Vivo Analyses of Ano-genital Wart Lymphocytes to Study the Human Papillomavirus Immune Response ACTA DERM-VENEREOL, v. 89
    Doi: http://doi.org/10.2340/00015555-0637
  • Stanley, MA., 2009. Immune responses to human papilloma viruses. Indian J Med Res, v. 130
  • Stanley, MA., 2009. Immunochemistry and Immunology of the Cervix
    Doi: http://doi.org/10.1002/9781444312744.ch4
  • Stanley, M., 2009. Early age of sexual debut: a risky experience J FAM PLAN REPROD H, v. 35
  • Winder, DM., Ball, SLR., Vaughan, K., Hanna, N., Woo, YL., Fränzer, J-T., Sterling, JC., Stanley, MA., Sudhoff, H. and Goon, PKC., 2009. Sensitive HPV detection in oropharyngeal cancers. BMC Cancer, v. 9
    Doi: http://doi.org/10.1186/1471-2407-9-440
  • 2008

  • Woo, YL., Sterling, JC., Crawford, R., van der Burg, SH., Coleman, N. and Stanley, M., 2008. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies Journal of Clinical Pathology, v. 61
    Doi: http://doi.org/10.1136/jcp.2008.056200
  • Goon, P., Sonnex, C., Jani, P., Stanley, M. and Sudhoff, H., 2008. Recurrent respiratory papillomatosis: an overview of current thinking and treatment EUR ARCH OTO-RHINO-L, v. 265
    Doi: http://doi.org/10.1007/s00405-007-0546-z
  • Dall, KL., Scarpini, CG., Roberts, I., Winder, DM., Stanley, MA., Muralidhar, B., Herdman, MT., Pett, MR. and Coleman, N., 2008. Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res, v. 68
    Doi: http://doi.org/10.1158/0008-5472.CAN-08-1741
  • Stanley, M., 2008. The epidemiology and burden of HPV disease. Nursing times, v. 104
  • Stanley, M., 2008. Human Papillomavirus Vaccines versus Cervical Cancer Screening Clinical Oncology, v. 20
    Doi: http://doi.org/10.1016/j.clon.2008.04.006
  • Woo, YL., Sterling, J., Damay, I., Coleman, N., Crawford, R., van der Burg, SH. and Stanley, M., 2008. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG, v. 115
    Doi: http://doi.org/10.1111/j.1471-0528.2008.01936.x
  • Stanley, M., 2008. HPV vaccines: are they the answer? BRIT MED BULL, v. 88
    Doi: http://doi.org/10.1093/bmb/ldn037
  • Stanley, M., 2008. Immunobiology of HPV and HPV vaccines Gynecologic Oncology, v. 109
    Doi: http://doi.org/10.1016/j.ygyno.2008.02.003
  • Roberts, I., Ng, G., Foster, N., Stanley, M., Herdman, MT., Pett, MR., Teschendorff, A. and Coleman, N., 2008. Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol, v. 8
    Doi: http://doi.org/10.1186/1472-6750-8-57
  • Stanley, M., Gissmann, L. and Nardelli-Haefliger, D., 2008. Immunobiology of Human Papillomavirus Infection and Vaccination - Implications for Second Generation Vaccines VACCINE, v. 26
    Doi: http://doi.org/10.1016/j.vaccine.2008.05.066
  • Woo, YL., Sterling, J., Crawford, R., van der Burg, SH., Coleman, N. and Stanley, M., 2008. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies. J Clin Pathol, v. 61
    Doi: http://doi.org/10.1136/jcp.2008.056200
  • Stanley, M., 2008. Immunobiology of HPV and HPV vaccines GYNECOL ONCOL, v. 109
    Doi: http://doi.org/10.1016/j.ygyno.2008.02.003
  • Skinner, SR., Garland, SM., Stanley, MA., Pitts, M. and Quinn, MA., 2008. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? MED J AUSTRALIA, v. 188
  • Woo, YL., Sterling, JC., Damay, I., Coleman, N., Crawford, R., van der Burg, SH. and Stanley, M., 2008. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis British Journal of Obstetrics and Gynaecology, v. 115
    Doi: http://doi.org/10.1111/j.1471-0528.2008.01936.x
  • Stanley, M. and Villa, LL., 2008. Monitoring HPV vaccination VACCINE, v. 26
    Doi: http://doi.org/10.1016/j.vaccine.2007.11.059
  • 2007

  • Woo, YL., Damay, I., Stanley, M., Crawford, R. and Sterling, JC., 2007. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens Journal of Virological Methods, v. 142
  • Stanley, M., 2007. Prophylactic HPV vaccines DRUGS TODAY, v. 43
  • Stanley, M., 2007. Prevention strategies against the human papillomavirus: The effectiveness of vaccination GYNECOL ONCOL, v. 107
    Doi: http://doi.org/10.1016/j.ygyno.2007.07.068
  • Winder, DM., Pett, MR., Foster, N., Shivji, MKK., Herdman, MT., Stanley, MA., Venkitaraman, AR. and Coleman, N., 2007. An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events. J Pathol, v. 213
    Doi: http://doi.org/10.1002/path.2206
  • Stanley, M., 2007. HPV vaccines: where are we now? J FAM PLAN REPROD H, v. 33
  • Stanley, M., 2007. Prophylactic HPV vaccines J CLIN PATHOL, v. 60
    Doi: http://doi.org/10.1136/jcp.2006.040568
  • Woo, YL., Damay, I., Stanley, M., Crawford, R. and Sterling, J., 2007. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens J VIROL METHODS, v. 142
    Doi: http://doi.org/10.1016/j.jviromet.2007.01.029
  • Stanley, M., 2007. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer BRIT J CANCER, v. 96
    Doi: http://doi.org/10.1038/sj.bjc.6603695
  • Stanley, MA., Pett, MR. and Coleman, N., 2007. HPV: from infection to cancer. Biochem Soc Trans, v. 35
    Doi: http://doi.org/10.1042/BST0351456
  • Stanley, M., 2007. Prevention strategies against the human papillomavirus: The effectiveness of vaccination Gynecologic Oncology, v. 107
    Doi: http://doi.org/10.1016/j.ygyno.2007.07.068
  • 2006

  • Stanley, M., 2006. Immune responses to human papillomavirus Vaccine, v. 24
    Doi: http://doi.org/10.1016/j.vaccine.2005.09.002
  • Herdman, MT., Pett, MR., Roberts, I., Alazawi, WOF., Teschendorff, AE., Zhang, X-Y., Stanley, MA. and Coleman, N., 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis, v. 27
    Doi: http://doi.org/10.1093/carcin/bgl172
  • Pett, MR., Herdman, MT., Palmer, RD., Yeo, GSH., Shivji, MK., Stanley, MA. and Coleman, N., 2006. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response P NATL ACAD SCI USA, v. 103
    Doi: http://doi.org/10.1073/pnas.0600078103
  • Stanley, M., 2006. Immune responses to genital HPV
    Doi: http://doi.org/10.1159/000092735
  • Stanley, M., Lowy, DR. and Frazer, I., 2006. Prophylactic HPV vaccines: Underlying mechanisms VACCINE, v. 24
    Doi: http://doi.org/10.1016/j.vaccine.2006.05.110
  • Stanley, M., 2006. Immune responses to human papillomavirus VACCINE, v. 24
    Doi: http://doi.org/10.1016/j.vaccine.2005.09.002
  • Stanley, M., 2006. HPV vaccines BEST PRACT RES CL OB, v. 20
    Doi: http://doi.org/10.1016/j.bpobgyn.2005.10.011
  • Jain, S., Moore, RA., Anderson, DM., Gough, GW. and Stanley, MA., 2006. Cell-mediated immune responses to COPV early proteins. Virology, v. 356
    Doi: http://doi.org/10.1016/j.virol.2006.07.032
  • Stanley, MA., 2006. Human papillomavirus vaccines. Rev Med Virol, v. 16
    Doi: http://doi.org/10.1002/rmv.498
  • Herdman, MT., Pett, MR., Roberts, I., Alazawi, WOF., Teschendorff, AE., Zhang, XY., Stanley, MA. and Coleman, N., 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants CARCINOGENESIS, v. 27
    Doi: http://doi.org/10.1093/carcin/bg1172
  • Stanley, M., Lowy, DR. and Frazer, I., 2006. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms Vaccine, v. 24
    Doi: http://doi.org/10.1016/j.vaccine.2006.05.110
  • 2005

  • Stanley, MA., 2005. Establishing HPV-containing keratinocyte cell lines from tissue biopsies. Methods Mol Med, v. 119
    Doi: http://doi.org/10.1385/1-59259-982-6:129
  • Johnston, KB., Monteiro, JM., Schultz, LD., Chen, L., Wang, FB., Ausensi, VA., Dell, EC., Santos, EB., Moore, RA., Palker, TJ., Stanley, MA. and Jansen, KU., 2005. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes VIROLOGY, v. 336
    Doi: http://doi.org/10.1016/j.virol.2005.03.022
  • Johnston, KB., Monteiro, JM., Schultz, LD., Chen, L., Wang, F., Ausensi, VA., Dell, EC., Santos, EB., Moore, RA., Palker, TJ., Stanley, MA. and Jansen, KU., 2005. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes Virology, v. 336
    Doi: http://doi.org/10.1016/j.virol.2005.03.022
  • Stanley, M., 2005. The end for genital human papillomavirus infections? LANCET ONCOL, v. 6
  • Lopez, MC. and Stanley, MA., 2005. Cytokine profile of mouse vaginal and uterus lymphocytes at estrus and diestrus. Clin Dev Immunol, v. 12
    Doi: http://doi.org/10.1080/17402520500141010
  • Stanley, MA., 2005. HPV vaccines - Reply J FAM PLAN REPROD H, v. 31
  • Stanley, MA., 2005. The imidazoquinolines - Mechanism of action and therapeutic potential in HPV-associated disease Papillomavirus Report, v. 16
    Doi: http://doi.org/10.1179/095741905X41267
  • Greenwood, K. and Stanley, MA., 2005. HPV vaccines [1] (multiple letters) Journal of Family Planning and Reproductive Health Care, v. 31
    Doi: http://doi.org/10.1783/0000000052972870
  • 2004

  • Pett, MR., Alazawi, WOF., Roberts, I., Dowen, S., Smith, DI., Stanley, MA. and Coleman, N., 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res, v. 64
    Doi: http://doi.org/10.1158/0008-5472.can-03-3214
  • Chakrabarti, O., Veeraraghavalu, K., Tergaonkar, V., Liu, Y., Androphy, EJ., Stanley, MA. and Krishna, S., 2004. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras J VIROL, v. 78
  • Chakrabarti, O., Veeraraghavalu, K., Tergaonkar, V., Liu, Y., Androphy, EJ., Stanley, MA. and Krishna, S., 2004. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by Notch signaling and oncogenic Ras Journal of Virology, v. 78
    Doi: http://doi.org/10.1128/JVI.78.11.5934-5945.2004
  • Veeraraghavalu, K., Pett, M., Kumar, RV., Nair, P., Rangarajan, A., Stanley, MA. and Krishna, S., 2004. Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in Jagged1 and manic fringe expression linked to notch activation J VIROL, v. 78
    Doi: http://doi.org/10.1128/JVI.78.16.8687.8700.2004
  • Stanley, MA., 2004. Human papillomavirus (HPV) vaccines: prospects for eradicating cervical cancer J FAM PLAN REPROD H, v. 30
  • Alazawi, W., Pett, M., Strauss, S., Moseley, R., Gray, J., Stanley, M. and Coleman, N., 2004. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer, v. 91
    Doi: http://doi.org/10.1038/sj.bjc.6602237
  • 2003

  • Stanley, M., 2003. Chapter 17: Genital human papillomavirus infections--current and prospective therapies. Journal of the National Cancer Institute. Monographs,
    Doi: http://doi.org/10.1093/oxfordjournals.jncimonographs.a003473
  • Stanley, M., 2003. Immune intervention in HPV infections: current progress and future developments. Expert Rev Vaccines, v. 2
    Doi: http://doi.org/10.1586/14760584.2.5.615
  • Stanley, MA., 2003. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines, v. 2
    Doi: http://doi.org/10.1586/14760584.2.3.381
  • Dowen, SE., Scott, A., Mukherjee, G. and Stanley, MA., 2003. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression International Journal of Cancer, v. 105
    Doi: http://doi.org/10.1002/ijc.11066
  • Anderson, DM., Stanley, MA. and White, RAS., 2003. Canine keratinocyte culture and use of a cultured epidermal autograft in a dog VET COMP ORTHOPAED, v. 16
  • Moore, RA., Walcott, S., White, KL., Anderson, DM., Jain, S., Lloyd, A., Topley, P., Thomsen, L., Gough, GW. and Stanley, MA., 2003. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology, v. 314
    Doi: http://doi.org/10.1016/s0042-6822(03)00465-3
  • Stanley, M., 2003. Untitled - Letter to the editor - Reply ISIS, v. 94
  • Baldwin, PJ., van der Burg, SH., Boswell, CM., Offringa, R., Hickling, JK., Dobson, J., Roberts, JSC., Latimer, JA., Moseley, RP., Coleman, N., Stanley, MA. and Sterling, JC., 2003. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res, v. 9
  • Stanley, M., 2003. Antibody reactivity to HPV E6 and E7 oncoproteins and early diagnosis of invasive cervical cancer AM J OBSTET GYNECOL, v. 188
    Doi: http://doi.org/10.1067/mob.2003.97
  • Dowen, SE., Neutze, DM., Pett, MR., Cottage, A., Stern, P., Coleman, N. and Stanley, MA., 2003. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene, v. 22
    Doi: http://doi.org/10.1038/sj.onc.1206296
  • Alazawi, WOF., Morris, LS., Stanley, MA., Garrod, DR. and Coleman, N., 2003. Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Virchows Arch, v. 443
    Doi: http://doi.org/10.1007/s00428-003-0771-9
  • Dowen, SE., Scott, A., Mukherjee, G. and Stanley, MA., 2003. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer, v. 105
    Doi: http://doi.org/10.1002/ijc.11066
  • 2002

  • Alazawi, W., Pett, M., Freeman, T., Stanley, M. and Coleman, N., 2002. Changes in host cell genome and transcriptome associated with integration of HPV 16 in cervical keratinocytes J PATHOL, v. 198
  • Moore, RA., Nicholls, PK., Santos, EB., Gough, GW. and Stanley, MA., 2002. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol, v. 83
    Doi: http://doi.org/10.1099/0022-1317-83-9-2299
  • Stanley, MA., 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol, v. 27
    Doi: http://doi.org/10.1046/j.1365-2230.2002.01151.x
  • Moore, RA., Santos, EB., Nicholls, PK., White, KL., Anderson, DM., Lloyd, A., Topley, P., Romanos, M., Thomsen, L., Parmar, V., Walcott, S., Gough, GW. and Stanley, MA., 2002. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology, v. 304
    Doi: http://doi.org/10.1006/viro.2002.1726
  • Sinclair, AM., Bench, AJ., Bloor, AJC., Li, J., Göttgens, B., Stanley, ML., Miller, J., Piltz, S., Hunter, S., Nacheva, EP., Sanchez, MJ. and Green, AR., 2002. Rescue of the lethal scl<sup>-/-</sup> phenotype by the human SCL locus Blood, v. 99
    Doi: http://doi.org/10.1182/blood.V99.11.3931
  • Alazawi, W., Pett, M., Arch, B., Scott, L., Freeman, T., Stanley, MA. and Coleman, N., 2002. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res, v. 62
  • Stanley, MA., 2002. Human papillomavirus vaccines. Curr Opin Mol Ther, v. 4
  • Stanley, MA., 2002. Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential H+G Zeitschrift fur Hautkrankheiten, v. 77
    Doi: http://doi.org/10.1046/j.1439-0353.2002.02627.x
  • Stanley, MA., 2002. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res, v. 89
    Doi: http://doi.org/10.1016/s0168-1702(02)00192-2
  • 2001

  • Stanley, MA., 2001. Immunobiology of papillomavirus infections. J Reprod Immunol, v. 52
    Doi: http://doi.org/10.1016/s0165-0378(01)00113-9
  • Cottage, A., Dowen, S., Roberts, I., Pett, M., Coleman, N. and Stanley, M., 2001. Early genetic events in HPV immortalised keratinocytes. Genes Chromosomes Cancer, v. 30
    Doi: http://doi.org/10.1002/1098-2264(2000)9999:9999<::aid-gcc1060>3.0.co;2-x
  • Mukherjee, G., Freeman, A., Moore, R., Kumaraswamy, , Devi, KU., Morris, LS., Coleman, N., Dilworth, S., Prabhakaran, PS. and Stanley, MA., 2001. Biologic factors and response to radiotherapy in carcinoma of the cervix INT J GYNECOL CANCER, v. 11
  • Li, YJ., Pak, BJ., Higgins, RR., Lu, SJ. and Ben-David, Y., 2001. Contiguous arrangement of p45 NFE2, HnRNP A1, and HP1α on mouse chromosome 15 and human chromosome 12: Evidence for suppression of these genes due to retroviral integration within the Fli-2 locus Genes Chromosomes and Cancer, v. 30
    Doi: http://doi.org/10.1002/1098-2264(2000)9999:9999<::AID-GCC1058>3.0.CO;2-A
  • Nicholls, PK., Moore, PF., Anderson, DM., Moore, RA., Parry, NR., Gough, GW. and Stanley, MA., 2001. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology, v. 283
    Doi: http://doi.org/10.1006/viro.2000.0789
  • Stanley, MA., Moore, RA., Nicholls, PK., Santos, EB., Thomsen, L., Parry, N., Walcott, S. and Gough, G., 2001. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine, v. 19
    Doi: http://doi.org/10.1016/s0264-410x(00)00533-8
  • Mukherjee, G., Freeman, A., Moore, R., Kumaraswamy, , Devi, KU., Morris, LS., Coleman, N., Dilworth, S., Prabhakaran, PS. and Stanley, MA., 2001. Biologic factors and response to radiotherapy in carcinoma of the cervix International Journal of Gynecological Cancer, v. 11
    Doi: http://doi.org/10.1046/j.1525-1438.2001.01014.x
  • Nicholls, PK., Doorbar, J., Moore, RA., Peh, W., Anderson, DM. and Stanley, MA., 2001. Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions. Virology, v. 284
    Doi: http://doi.org/10.1006/viro.2001.0868
  • Stanley, MA., 2001. Human papillomavirus and cervical carcinogenesis. Best Pract Res Clin Obstet Gynaecol, v. 15
    Doi: http://doi.org/10.1053/beog.2001.0213
  • 2000

  • Nicholls, PK. and Stanley, MA., 2000. The immunology of animal papillomaviruses. Vet Immunol Immunopathol, v. 73
    Doi: http://doi.org/10.1016/s0165-2427(99)00165-8
  • Arany, I., Tyring, SK., Brysk, MM., Stanley, MA., Tomai, MA., Miller, RL., Smith, MH., McDermott, DJ. and Slade, HB., 2000. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts ANTIMICROB AGENTS CH, v. 44
  • López, MC. and Stanley, MA., 2000. Cytokine profile of draining lymph node lymphocytes in mice grafted with syngeneic keratinocytes expressing human papillomavirus type 16 E7 protein. J Gen Virol, v. 81
    Doi: http://doi.org/10.1099/0022-1317-81-5-1175
  • 1999

  • Arany, I., Tyring, SK., Stanley, MA., Tomai, MA., Miller, RL., Smith, MH., McDermott, DJ. and Slade, HB., 1999. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5% ANTIVIR RES, v. 43
  • Pett, MR., Roberts, IR., Stanley, MA. and Coleman, N., 1999. The cell line W12 as a model for investigation of genomic events associated with the progression of cervical squamous cell carcinoma. AM J HUM GENET, v. 65
  • Nicholls, PK., Klaunberg, BA., Moore, RA., Santos, EB., Parry, NR., Gough, GW. and Stanley, MA., 1999. Naturally occurring, nonregressing canine oral papillomavirus infection: Host immunity, virus characterization, and experimental infection VIROLOGY, v. 265
  • Nicholls, PK. and Stanley, MA., 1999. Canine papillomavirus--A centenary review. J Comp Pathol, v. 120
    Doi: http://doi.org/10.1053/jcpa.1998.0278
  • 1998

  • Cubie, HA., Plumstead, M., Zhang, W., de Jesus, O., Duncan, LA. and Stanley, MA., 1998. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls J MED VIROL, v. 56
  • Zhang, W., Carmichael, J., Ferguson, J., Inglis, S., Ashrafian, H. and Stanley, M., 1998. Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. Virology, v. 243
    Doi: http://doi.org/10.1006/viro.1998.9050
  • Cubie, HA., Plumstead, M., Zhang, W., De Jesus, O., Duncan, LA. and Stanley, MA., 1998. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls Journal of Medical Virology, v. 56
    Doi: http://doi.org/10.1002/(SICI)1096-9071(199811)56:3<210::AID-JMV6>3.0.CO;2-A
  • Masterson, PJ., Stanley, MA., Lewis, AP. and Romanos, MA., 1998. A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit. J Virol, v. 72
    Doi: http://doi.org/10.1128/JVI.72.9.7407-7419.1998
  • 1997

  • Stanley, M., 1997. Genital human papillomaviruses - Prospects for vaccination CURR OPIN INFECT DIS, v. 10
  • Ngan, HYS., Tsao, SW., Liu, SS. and Stanley, M., 1997. Abnormal expression and mutation of p53 in cervical cancer - A study at protein, RNA and DNA levels GENITOURIN MED, v. 73
  • Ngan, HYS., Tsao, SW., Liu, SS. and Stanley, M., 1997. Abnormal expression and mutation of p53 in cervical cancer - A study at protein, RNA and DNA levels Sexually Transmitted Infections, v. 73
    Doi: http://doi.org/10.1136/sti.73.1.54
  • Bartholomew, JS., Glenville, S., Sarkar, S., Burt, DJ., Stanley, MA., RuizCabello, F., Jin, CG., Garrido, F. and Stern, PL., 1997. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells CANCER RES, v. 57
  • DietrichGoetz, W., Kennedy, IM., Levins, B., Stanley, MA. and Clements, JB., 1997. A cellular 65-kDa protein recognizes the negative regulatory element of human papillomavirus late mRNA P NATL ACAD SCI USA, v. 94
  • Stanley, MA., Masterson, PJ. and Nicholls, PK., 1997. In vitro and animal models for antiviral therapy in papillomavirus infections ANTIVIR CHEM CHEMOTH, v. 8
  • Stanley, M., 1997. ands, North Queensland, Australia, 6-9 December 1996 ... MOL MED TODAY, v. 3
  • Wells, JCK., Stanley, M., Laidlaw, A., Day, JME., Stafford, M. and Davies, PSW., 1997. Investigation of the relationship between infant temperament and later body composition INT J OBESITY, v. 21
  • 1996

  • Wu, R., Coleman, N. and Stanley, M., 1996. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity CHINESE MED J-PEKING, v. 109
  • Loughran, O., Malliri, A., Owens, D., Gallimore, PH., Stanley, MA., Ozanne, B., Frame, MC. and Parkinson, EK., 1996. Association of CDKN2A/p16(INK4A) with human head and neck keratinocyte replicative senescence: Relationship of dysfunction to immortality and neoplasia ONCOGENE, v. 13
  • 1995

  • Johnsen, CK., Stanley, M. and Norrild, B., 1995. Analysis of human papillomavirus type 16 E5 oncogene expression in vitro and from bicistronic messenger RNAs INTERVIROLOGY, v. 38
  • STANLEY, M., PARIKH, J., CHAMBERS, M., HIBMA, M. and ZHANG, W., 1995. SEROLOGICAL RESPONSES TO HPV 16 E7 PROTEIN IN A MOUSE MODEL J CELL BIOCHEM,
  • Raj, K. and Stanley, MA., 1995. The ATP-binding and ATPase activities of human papillomavirus type 16 E1 are significantly weakened by the absence of prolines in its ATP-binding domain. J Gen Virol, v. 76 ( Pt 12)
    Doi: http://doi.org/10.1099/0022-1317-76-12-2949
  • HIBMA, MH., RAJ, K., ELY, SJ., STANLEY, M. and CRAWFORD, L., 1995. THE INTERACTION BETWEEN HUMAN PAPILLOMAVIRUS TYPE-16 E1 AND E2 PROTEINS IS BLOCKED BY AN ANTIBODY TO THE N-TERMINAL REGION OF E2 EUR J BIOCHEM, v. 229
  • 1994

  • Chambers, MA., Wei, Z., Coleman, N., Nash, AA. and Stanley, MA., 1994. "Natural" presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur J Immunol, v. 24
    Doi: http://doi.org/10.1002/eji.1830240337
  • Stanley, M., Coleman, N. and Chambers, M., 1994. The host response to lesions induced by human papillomavirus. Ciba Found Symp, v. 187
  • NGAN, HYS., STANLEY, M., LIU, SS. and MA, HK., 1994. HPV AND P53 IN CERVICAL-CANCER GENITOURIN MED, v. 70
  • Coleman, N. and Stanley, MA., 1994. Expression of the myelomonocytic antigens CD36 and L1 by keratinocytes in squamous intraepithelial lesions of the cervix. Hum Pathol, v. 25
    Doi: http://doi.org/10.1016/0046-8177(94)90174-0
  • Coleman, N. and Stanley, MA., 1994. Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus-related disease of the cervix. Cancer, v. 74
    Doi: http://doi.org/10.1002/1097-0142(19940801)74:3<884::aid-cncr2820740315>3.0.co;2-…
  • Coleman, N., Birley, HD., Renton, AM., Hanna, NF., Ryait, BK., Byrne, M., Taylor-Robinson, D. and Stanley, MA., 1994. Immunological events in regressing genital warts. Am J Clin Pathol, v. 102
    Doi: http://doi.org/10.1093/ajcp/102.6.768
  • Stanley, MA., 1994. Replication of human papillomaviruses in cell culture. Antiviral Res, v. 24
    Doi: http://doi.org/10.1016/0166-3542(94)90047-7
  • Chambers, MA., Stacey, SN., Arrand, JR. and Stanley, MA., 1994. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. J Gen Virol, v. 75 ( Pt 1)
    Doi: http://doi.org/10.1099/0022-1317-75-1-165
  • Coleman, N. and Stanley, MA., 1994. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer, v. 56
    Doi: http://doi.org/10.1002/ijc.2910560303
  • 1993

  • COLEMAN, N., FOX, SB., MICHIE, CA., SCHALL, TJ. and STANLEY, MA., 1993. LYMPHOCYTE TRAFFICKING TO THE CERVIX IN LOW AND HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS J CELL BIOCHEM,
  • STANLEY, MA. and CHAMBERS, MA., 1993. A DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO HUMAN PAPILLOMAVIRUS TYPE-16 (HPV16) PROTEINS J CELL BIOCHEM,
  • Sterling, JC., Skepper, JN. and Stanley, MA., 1993. Immunoelectron microscopical localization of human papillomavirus type 16 L1 and E4 proteins in cervical keratinocytes cultured in vivo. J Invest Dermatol, v. 100
    Doi: http://doi.org/10.1111/1523-1747.ep12462790
  • McLean, CS., Sterling, JC., Mowat, J., Nash, AA. and Stanley, MA., 1993. Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model Journal of General Virology, v. 74
  • Coleman, N., Greenfield, IM., Hare, J., Kruger-Gray, H., Chain, BM. and Stanley, MA., 1993. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes. Am J Pathol, v. 143
  • McLean, CS., Sterling, JS., Mowat, J., Nash, AA. and Stanley, MA., 1993. Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. J Gen Virol, v. 74 ( Pt 2)
    Doi: http://doi.org/10.1099/0022-1317-74-2-239
  • 1992

  • COLEMAN, N., WILSON, B. and STANLEY, MA., 1992. CELLULAR AND MOLECULAR MECHANISMS INVOLVED IN EFFECTIVE IMMUNE-RESPONSES TO HUMAN PAPILLOMAVIRUS INFECTION IN THE GENITAL-TRACT J PATHOL, v. 168
  • LEARY, T., JONES, PL., APPLEBY, M., BLIGHT, A., PARKINSON, K. and STANLEY, M., 1992. EPIDERMAL KERATINOCYTE SELF-RENEWAL IS DEPENDENT UPON DERMAL INTEGRITY J INVEST DERMATOL, v. 99
  • STOREY, A., GREENFIELD, I., BANKS, L., PIM, D., CROOK, T., CRAWFORD, L. and STANLEY, M., 1992. LACK OF IMMORTALIZING ACTIVITY OF A HUMAN PAPILLOMAVIRUS TYPE-16 VARIANT DNA WITH A MUTATION IN THE E2 GENE ISOLATED FROM NORMAL HUMAN CERVICAL KERATINOCYTES ONCOGENE, v. 7
  • 1991

  • STERLING, JC., MINSON, AC., STANLEY, MA., GATWARD, G. and SKEPPER, J., 1991. CULTURE OF HUMAN PAPILLOMAVIRUS TYPE-16 CONTAINING KERATINOCYTES INVIVO RESULTING IN THE DEVELOPMENT OF A DIFFERENTIATED EPITHELIUM WITH COMPLETION OF THE VIRUS LIFE-CYCLE J PATHOL, v. 163
  • GREENFIELD, I., NICKERSON, J., PENMAN, S. and STANLEY, M., 1991. HUMAN PAPILLOMAVIRUS-16 E7-PROTEIN IS ASSOCIATED WITH THE NUCLEAR MATRIX P NATL ACAD SCI USA, v. 88
  • MCKENZIE, J., KING, A., HARE, J., FULFORD, T., WILSON, B. and STANLEY, M., 1991. IMMUNOCYTOCHEMICAL CHARACTERIZATION OF LARGE GRANULAR LYMPHOCYTES IN NORMAL CERVIX AND HPV ASSOCIATED DISEASE J PATHOL, v. 165
  • JONES, PL., GREENFIELD, IM., COLEMAN, N. and STANLEY, MA., 1991. HISTOLOGICAL CHARACTERIZATION OF MOUSE EPIDERMAL KERATINOCYTE CELL-LINES TRANSFECTED WITH ACTIVATED RAS ONCOGENES J PATHOL, v. 163
  • JONES, PL., GREENFIELD, IM., COLEMAN, N. and STANLEY, MA., 1991. HISTOLOGICAL CHARACTERIZATION OF MOUSE EPIDERMAL KERATINOCYTE CELL-LINES TRANSFECTED WITH ACTIVATED RAS ONCOGENES J PATHOL, v. 163
  • STANLEY, MA., WILLIAMS, AT. and GREENFIELD, IM., 1991. CHARACTERIZATION OF A CELL-LINE CULTURED FROM A HISTOLOGICALLY NORMAL CERVIX J PATHOL, v. 163
  • STANLEY, MA., LEARY, T., JONES, PL., BLIGHT, A. and PARKINSON, EK., 1991. EPIDERMAL KERATINOCYTE SELF RENEWAL IS DEPENDENT UPON DERMAL INTEGRITY J INVEST DERMATOL, v. 96
  • 1990

  • Yeoman, H., Munro, AJ. and Stanley, MA., 1990. Rejection of MHC incompatible, Langerhans cell-free epidermal keratinocyte allografts in the rat Regional Immunology, v. 3
  • McLean, CS., Churcher, MJ., Meinke, J., Smith, GL., Higgins, G., Stanley, M. and Minson, AC., 1990. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol, v. 43
    Doi: http://doi.org/10.1136/jcp.43.6.488
  • Sterling, JC., Stanley, MA., Gatward, G. and Minson, AC., 1990. Production of human papillomavirus type 16 visions in a keratinocyte cell line. Journal of Virology, v. 64
  • Zhou, J., Crawford, L., McLean, L., Sun, X., Stanley, M., Almond, N. and Smith, GL., 1990. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes Journal of General Virology, v. 71
    Doi: http://doi.org/10.1099/0022-1317-71-9-2185
  • STANLEY, M., 1990. GENITAL PAPILLOMAVIRUSES, POLYMERASE CHAIN-REACTION AND CERVICAL-CANCER GENITOURIN MED, v. 66
  • STERLING, J., STANLEY, M., GATWARD, G. and MINSON, T., 1990. PRODUCTION OF HUMAN PAPILLOMAVIRUS TYPE-16 VIRIONS IN A KERATINOCYTE CELL-LINE J VIROL, v. 64
  • DOORBAR, J., PARTON, A., HARTLEY, K., BANKS, L., CROOK, T., STANLEY, M. and CRAWFORD, L., 1990. DETECTION OF NOVEL SPLICING PATTERNS IN A HPV16-CONTAINING KERATINOCYTE CELL-LINE VIROLOGY, v. 178
  • CROOK, T., GREENFIELD, I., HOWARD, J. and STANLEY, M., 1990. ALTERATIONS IN GROWTH-PROPERTIES OF HUMAN PAPILLOMA-VIRUS TYPE-16 IMMORTALIZED HUMAN CERVICAL KERATINOCYTE CELL-LINE CORRELATE WITH AMPLIFICATION AND OVEREXPRESSION OF C-MYC ONCOGENE ONCOGENE, v. 5
  • TINOIS, E., COBBOLD, S., FAURE, M., STANLEY, M. and THIVOLET, J., 1990. CULTURED KERATINOCYTE GRAFTS ARE RECOGNIZED, BUT NOT REJECTED BY CD8+ T-CELLS INVIVO J INVEST DERMATOL, v. 94
  • 1989

  • TINOIS, E., COBBOLD, S., FAURE, M., YEOMAN, H. and STANLEY, M., 1989. CULTURED KERATINOCYTE GRAFTS ARE RECOGNIZED, BUT NOT REJECTED BY CD8+ T-CELLS INVIVO EUR J IMMUNOL, v. 19
  • TINOIS, E., FAURE, M., COBBOLD, S., YEOMAN, H., STANLEY, M. and THIVOLET, J., 1989. CULTURED MURINE EPIDERMAL ALLOGRAFTS INDUCE A PROLONGED SURVIVAL OF FULL THICKNESS SKIN ALLOGRAFTS CLIN RES, v. 37
  • Appleby, MW., Greenfield, IM., Crook, T., Parkinson, EK. and Stanley, MA., 1989. In vivo and in vitro effects of v-fos and EJ-Ha-ras oncogene expression in murine epidermal keratinocytes. Oncogene, v. 4
  • Yeoman, H., Ramrakha, PS., Sharp, RJ. and Stanley, MA., 1989. The role of antigen-presenting cells in the survival of murine-cultured keratinocyte allografts Transplantation Proceedings, v. 21
  • TINOIS, E., FAURE, M., COBBOLD, S., YEOMAN, H., STANLEY, M. and THIVOLET, J., 1989. CULTURED MURINE EPIDERMAL ALLOGRAFTS INDUCE A PROLONGED SURVIVAL OF FULL THICKNESS SKIN ALLOGRAFTS J INVEST DERMATOL, v. 92
  • Yeoman, H., Anderton, JG. and Stanley, MA., 1989. MHC class II antigen expression is not induced on murine epidermal keratinocytes by interferon-gamma alone or in combination with tumour necrosis factor-alpha. Immunology, v. 66
  • Crook, T., Almond, N., Murray, A., Stanley, M. and Crawford, L., 1989. Constitutive expression of c-myc oncogene confers hormone independence and enhanced growth-factor responsiveness on cells transformed by human papilloma virus type 16. Proc Natl Acad Sci U S A, v. 86
    Doi: http://doi.org/10.1073/pnas.86.15.5713
  • Ramrakha, PS., Sharp, RJ., Yeoman, H. and Stanley, MA., 1989. The influence of MHC-compatible and MHC-incompatible antigen-presenting cells on the survival of MHC-compatible cultured murine keratinocyte allografts. Transplantation, v. 48
  • Yeoman, H., Ramrakha, PS., Sharp, RJ. and Stanley, MA., 1989. The role of antigen-presenting cells in the survival of murine-cultured keratinocyte allografts. Transplant Proc, v. 21
  • Stanley, MA., Browne, HM., Appleby, M. and Minson, AC., 1989. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer, v. 43
    Doi: http://doi.org/10.1002/ijc.2910430422
  • 1988

  • Browne, HM., Churcher, MJ., Stanley, MA., Smith, GL. and Minson, AC., 1988. Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant. J Gen Virol, v. 69 ( Pt 6)
    Doi: http://doi.org/10.1099/0022-1317-69-6-1263
  • MATLASHEWSKI, G., OSBORN, K., BANKS, L., STANLEY, M. and CRAWFORD, L., 1988. TRANSFORMATION OF PRIMARY HUMAN FIBROBLAST CELLS WITH HUMAN PAPILLOMAVIRUS TYPE-16 DNA AND EJ-RAS INT J CANCER, v. 42
  • VANHERCKENRODE, CM., COLEMAN, DJ., STANLEY, M. and KOCH, GLE., 1988. ANTIBODIES SPECIFIC FOR HELA GLYCOPROTEIN ANTIGENS ARE ALSO SPECIFIC FOR HUMAN ENDOCERVICAL EPITHELIUM BRIT J CANCER, v. 57
  • Thorne, KJI., Richardson, BA., Butterworth, AE. and Stanley, M., 1988. Eosinophil-activating factor (EAF) production by a human cell line (ESH 98) stimulated with tumour necrosis factor Immunology, v. 63
  • 1987

  • HAMMOND, EJ., NG, RLH., STANLEY, MA. and MUNRO, AJ., 1987. PROLONGED SURVIVAL OF CULTURED KERATINOCYTE ALLOGRAFTS IN THE NONIMMUNOSUPPRESSED MOUSE TRANSPLANTATION, v. 44
  • APPLEBY, MW., STANLEY, MA. and PARKINSON, EK., 1987. THE IDENTIFICATION OF A KERATINOCYTE SUBPOPULATION RESISTANT TO SUSPENSION INDUCED TERMINAL DIFFERENTIATION ANTICANCER RES, v. 7
  • 1986

  • BLANK, H., HOWLEY, P., VESSEY, MP., SHAH, KV., COLEMAN, DV., MCCANCE, DJ., LANCSTER, WD., GALLOWAY, DA., GISSMANN, L., ANDROPHY, ET., STEINBERG, BM., STANLEY, M., PFISTER, H. and CAMPO, MS., 1986. EPIDEMIOLOGIC TRENDS AND LEGAL-ASPECTS - GENERAL DISCUSSION CIBA F SYMP, v. 120
  • HAMMOND, EJ., NG, R. and STANLEY, MA., 1986. PROLONGED SURVIVAL OF ALLOGENEIC CULTURED EPIDERMAL KERATINOCYTE SHEETS IN THE MOUSE WITHOUT IMMUNOSUPPRESSION J INVEST DERMATOL, v. 87
  • PEAT, DS. and STANLEY, MA., 1986. CHROMOSOME-DAMAGE INDUCED BY HERPES-SIMPLEX VIRUS TYPE-1 IN EARLY INFECTION J GEN VIROL, v. 67
  • 1985

  • DIXON, IS. and STANLEY, MA., 1985. DIFFERENTIATION OF HUMAN CERVICAL EPITHELIA INVIVO AND INVITRO J PATHOL, v. 145
  • STANLEY, MA., CROWCROFT, NS., QUIGLEY, JP. and PARKINSON, FK., 1985. RESPONSES OF HUMAN CERVICAL KERATINOCYTES INVITRO TO TUMOR PROMOTERS AND DIETHYLSTILBESTROL CARCINOGENESIS, v. 6
  • 1984

  • DIXON, IS. and STANLEY, MA., 1984. IMMUNOFLUORESCENT STUDIES ON THE CYTOSKELETON OF HUMAN CERVICAL EPITHELIUM INVIVO AND INVITRO EUR J CELL BIOL, v. 33
  • STANLEY, MA. and DAHLENBURG, K., 1984. THE EFFECT OF CHOLERAGEN AND EPIDERMAL GROWTH-FACTOR ON PROLIFERATION AND MATURATION INVITRO OF HUMAN ECTOCERVICAL CELLS IN VITRO CELL DEV B, v. 20
  • Dixon, IS. and Stanley, MA., 1984. Immunofluorescent studies of human cervical epithelia in vivo and in vitro using antibodies against specific keratin components Molecular Biology and Medicine, v. 2
  • STANLEY, MA., JOHNSTONE, SR. and QUIGLEY, JR., 1984. EFFECT DIETHYLSTILBESTROL ON GROWTH OF HUMAN CERVICAL CELLS-INVITRO J PATHOL, v. 142
  • JOHNSTONE, SRD., STANLEY, MA. and QUIGLEY, JP., 1984. THE EFFECT OF DIETHYLSTILBESTROL ON THE INVITRO GROWTH OF HUMAN ECTOCERVICAL CELLS CARCINOGENESIS, v. 5
  • 1982

  • STANLEY, MA. and DAHLENBURG, K., 1982. THE EFFECT OF CHOLERA-TOXIN AND EPIDERMAL GROWTH-FACTOR ON THE INVITRO GROWTH OF HUMAN CERVICAL EPITHELIUM J PATHOL, v. 138
  • Book chapters

    2015

  • Stanley, M., 2015. Human papilloma virus vaccines
    Doi: http://doi.org/10.1007/978-3-319-12406-3_9
  • 2011

  • Stanley, M., 2011. Therapeutic vaccines for HPV infection
    Doi: http://doi.org/10.1007/978-1-4614-1988-4_12
  • Stanley, M., 2011. Pathobiology and immunology of human papillomavirus
    Doi: http://doi.org/10.2217/EBO.11.115
  • Conference proceedings

    2012

  • Coleman, N., Barker, EM., Burrows, JE., Scarpini, CGS., Gay, NJ., Stanley, MA. and Pett, MR., 2012. Human Papillomavirus Type 16 Episomes Inhibit Cellular Responses to Double-stranded RNA JOURNAL OF PATHOLOGY, v. 226
  • 2009

  • Stanley, M., 2009. Immune responses to genital HPV infection and prophylactic vaccines JOURNAL OF REPRODUCTIVE IMMUNOLOGY, v. 81
    Doi: http://doi.org/10.1016/j.jri.2009.06.170
  • 2006

  • Pett, MR., Herdman, MT., Palmer, RD., Shivji, MK., Yeo, GS., Stanley, MA. and Coleman, N., 2006. Identification of a key step in cervical carcinogenesis: Selection of integrated high risk human papillomavirus correlates with episome loss and an endogenous antiviral response JOURNAL OF PATHOLOGY, v. 208
  • Herdman, MT., Pett, MR., Roberts, I., Alazawi, WOF., Teschendorft, AE., Zhang, XY., Stanley, MA. and Coleman, N., 2006. Interferon-beta promotes rapid episomal loss and the emergence of latent integrants in cervical keratinocytes infected with human papillomavirus type 16 JOURNAL OF PATHOLOGY, v. 208
  • 2003

  • Gottgens, B., Kinston, S., Nastos, A., Piltz, S., Delabesse, ECM., Stanley, M., Silberstein, L., Sanchez, MJ., Uitz, AC., Patient, R. and Green, AR., 2003. Establishing the transcriptional programme for blood: Transcriptional regulation of the SCL/TAL-1 gene. BLOOD CELLS MOLECULES AND DISEASES, v. 31
  • Pett, MR., Alazawi, W., Dowen, S., Roberts, I., Stanley, MA. and Coleman, N., 2003. Acquisition of high-level genomic instability is associated with integration of HPV16 in cervical keratinocytes JOURNAL OF PATHOLOGY, v. 201
  • 1998

  • Tyring, SK., Arany, I., Stanley, MA., Tomai, MA., Miller, RL., Smith, MH., McDermott, DJ. and Slade, HB., 1998. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod JOURNAL OF INFECTIOUS DISEASES, v. 178
  • Stanley, M., 1998. The immunology of genital human papilloma virus infection EUROPEAN JOURNAL OF DERMATOLOGY, v. 8
  • 1994

  • FRAZER, IH., STANLEY, M., CAMPO, MS., GALLOWAY, DA., MELIEF, CJM., DOHERTY, PC., EISENBERG, L., GREENBERG, P., WETTSTEIN, FO., LEVITSKY, H., MOSS, DJ., ARRAND, JP., RICKINSON, AB., CHEN, L., CRESSWELL, P. and PARHAM, P., 1994. VACCINES AGAINST VIRALLY INDUCED CANCERS - FINAL DISCUSSION VACCINES AGAINST VIRALLY INDUCED CANCERS, v. 187
  • ALLISON, JP., EISENBACH, L., LIEW, FY., STANLEY, M., LEVITSKY, H., CHEN, L. and GREENBERG, P., 1994. ANTIGEN-PRESENTING CELLS - GENERAL DISCUSSION-II VACCINES AGAINST VIRALLY INDUCED CANCERS, v. 187
  • 1990

  • GREENFIELD, IM., APPLEBY, MW., CROOK, T. and STANLEY, MA., 1990. THE INFLUENCE OF HUMAN PAPILLOMAVIRUS-16 AND OTHER ONCOGENES ON MURINE KERATINOCYTES INVITRO AND INVIVO PAPILLOMAVIRUSES ///, v. 124